Enliven Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 45.08 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.30B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe...